Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma
This study will determine the highest tolerable dose of CP-675,206 when given in combination with SU011248.
Carcinoma, Renal Cell
DRUG: CP-675,206|DRUG: SU011248|DRUG: CP-675,206|DRUG: SU011248
To determine the highest tolerable dose of CP-675,206 that can be combined with SU011248. The safety observation period will be 6 weeks from the first dose of study drug, 6 weeks after first dose
To allow for the possibility of genotyping should an unexpected outcome or an increase in unexplained adverse events be reported, 18 months|To evaluate the pharmacokinetics (PK) of CP-675,206 and SU011248 when given in combination, up to 18 months|To monitor for an antibody response to CP-675,206, up to 18 months|To assess any preliminary evidence of anti-tumor activity: 6-18 months after last subject enrolled, 6-18 months after last subject enrolled
This study will determine the highest tolerable dose of CP-675,206 when given in combination with SU011248.